1. Home
  2. CELU vs GRML Comparison

CELU vs GRML Comparison

Compare CELU & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Celularity Inc.

CELU

Celularity Inc.

HOLD

Current Price

$1.00

Market Cap

35.2M

Sector

Health Care

ML Signal

HOLD

GRML

Greenland Mines Ltd. Common Stock

N/A

Current Price

$0.46

Market Cap

41.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CELU
GRML
Founded
2016
N/A
Country
United States
United States
Employees
123
5
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.2M
41.9M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
CELU
GRML
Price
$1.00
$0.46
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$6.00
N/A
AVG Volume (30 Days)
24.3K
3.6M
Earning Date
05-11-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$76.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.01
$0.27
52 Week High
$4.35
$0.49

Technical Indicators

Market Signals
Indicator
CELU
GRML
Relative Strength Index (RSI) 25.14 58.00
Support Level N/A $0.31
Resistance Level $1.46 N/A
Average True Range (ATR) 0.08 0.06
MACD -0.03 0.01
Stochastic Oscillator 3.55 77.37

Price Performance

Historical Comparison
CELU
GRML

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

About GRML Greenland Mines Ltd. Common Stock

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.

Share on Social Networks: